Satellos Bioscience Inc. (MSCL) — Cash Flow-to-Debt Ratio
Satellos Bioscience Inc. (MSCL) has a Cash Flow-to-Debt Ratio of -1.80x as of December 2025, meaning its operating cash flow of CA$-7.38 Million could theoretically repay -2% of its total liabilities (CA$4.10 Million) in one year. See working capital to net assets of Satellos Bioscience Inc. to evaluate short-term liquidity relative to the company's equity base.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Satellos Bioscience Inc. Cash Flow-to-Debt Ratio (2019–2025)
Historical debt coverage capacity for Satellos Bioscience Inc. across 7 annual periods. Also explore Satellos Bioscience Inc. equity growth rate to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Satellos Bioscience Inc. (2019–2025)
Year-by-year debt coverage analysis for Satellos Bioscience Inc.. For market capitalisation and broader financial context, see market value of Satellos Bioscience Inc..
| Year | CF-to-Debt Ratio | Operating CF (CAD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -5.86x | CA$-24.01 Million | CA$4.10 Million | ▼ -20.9% |
| 2024 | -4.84x | CA$-24.98 Million | CA$5.16 Million | ▼ -21.8% |
| 2023 | -3.98x | CA$-14.42 Million | CA$3.62 Million | ▼ -94.7% |
| 2022 | -2.04x | CA$-5.78 Million | CA$2.83 Million | ▲ +14.6% |
| 2021 | -2.39x | CA$-5.03 Million | CA$2.10 Million | ▼ -89.3% |
| 2020 | -1.26x | CA$-1.66 Million | CA$1.31 Million | ▲ +56.3% |
| 2019 | -2.89x | CA$-1.92 Million | CA$664.81K | — |